453 related articles for article (PubMed ID: 16444866)
1. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
3. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
Dayal S; Rodionov RN; Arning E; Bottiglieri T; Kimoto M; Murry DJ; Cooke JP; Faraci FM; Lentz SR
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H816-25. PubMed ID: 18567702
[TBL] [Abstract][Full Text] [Related]
5. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP
Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652
[TBL] [Abstract][Full Text] [Related]
8. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
12. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Magné J; Huneau JF; Borderie D; Mathé V; Bos C; Mariotti F
Amino Acids; 2015 Sep; 47(9):1975-82. PubMed ID: 25792109
[TBL] [Abstract][Full Text] [Related]
13. Protection of DDAH2 overexpression against homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells.
Liu LH; Guo Z; Feng M; Wu ZZ; He ZM; Xiong Y
Cell Physiol Biochem; 2012; 30(6):1413-22. PubMed ID: 23171931
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
15. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.
Pope AJ; Karrupiah K; Kearns PN; Xia Y; Cardounel AJ
J Biol Chem; 2009 Dec; 284(51):35338-47. PubMed ID: 19820234
[TBL] [Abstract][Full Text] [Related]
16. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
Yin QF; Fu SH; He P; Xiong Y
Atherosclerosis; 2007 Jan; 190(1):53-61. PubMed ID: 16533509
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
McCarty MF
Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
Dayoub H; Rodionov RN; Lynch C; Cooke JP; Arning E; Bottiglieri T; Lentz SR; Faraci FM
Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Böger RH; Vallance P; Cooke JP
Atheroscler Suppl; 2003 Dec; 4(4):1-3. PubMed ID: 14664896
[No Abstract] [Full Text] [Related]
20. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
Feng M; Liu L; Guo Z; Xiong Y
Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
